Literature DB >> 2675755

Mode of action of the dual-action cephalosporin Ro 23-9424.

N H Georgopapadakou1, A Bertasso, K K Chan, J S Chapman, R Cleeland, L M Cummings, B A Dix, D D Keith.   

Abstract

Ro 23-9424 is a broad-spectrum antibacterial agent composed of a cephalosporin and a quinolone moiety. Its biological properties were compared with those of its two components and structurally related cephalosporins and quinolones. Like ceftriaxone and cefotaxime but unlike its decomposition product, desacetyl cefotaxime, Ro 23-9424 bound at less than or equal to 2 micrograms/ml to the essential penicillin-binding proteins 1b and 3 of Escherichia coli and 1, 2, and 3 of Staphylococcus aureus. In E. coli, Ro 23-9424 produced filaments exclusively and decreased cell growth; cefotaxime produced both filaments and lysis. Like its decomposition product fleroxacin but unlike quinolone esters, Ro 23-9424 also inhibited replicative DNA biosynthesis in E. coli. In an E. coli strain lacking OmpF, growth continued after addition of Ro 23-9424, decreased after addition of cefotaxime, and stopped immediately after addition of fleroxacin. The results, together with the chemical stability of Ro 23-9424 (half-life, approximately 3 h at pH 7.4 and 37 degrees C), suggest that in E. coli the compound acts initially as a cephalosporin with intrinsic activity comparable to that of cefotaxime but with poorer penetration. Subsequent to the decomposition of Ro 23-9424 to fleroxacin and desacetyl cefotaxime, quinolone activity appears. The in vitro antibacterial activity reflects both mechanisms of action.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2675755      PMCID: PMC176063          DOI: 10.1128/AAC.33.7.1067

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  19 in total

1.  Mechanism of action of nalidixic acid: purification of Escherichia coli nalA gene product and its relationship to DNA gyrase and a novel nicking-closing enzyme.

Authors:  A Sugino; C L Peebles; K N Kreuzer; N R Cozzarelli
Journal:  Proc Natl Acad Sci U S A       Date:  1977-11       Impact factor: 11.205

2.  A new cephalosporin with a dual mode of action.

Authors:  C H O'Callaghan; R B Sykes; S E Staniforth
Journal:  Antimicrob Agents Chemother       Date:  1976-08       Impact factor: 5.191

3.  Studies on the mode of action of nalidixic acid.

Authors:  A M Pedrini; D Geroldi; A Siccardi; A Falaschi
Journal:  Eur J Biochem       Date:  1972-02-15

4.  Replication and repair of DNA in cells of Escherichia coli treated with toluene.

Authors:  R E Moses; C C Richardson
Journal:  Proc Natl Acad Sci U S A       Date:  1970-10       Impact factor: 11.205

5.  Mutant drug resistant factors of high transmissibility.

Authors:  E Meynell; N Datta
Journal:  Nature       Date:  1967-05-27       Impact factor: 49.962

6.  Properties of the penicillin-binding proteins of Escherichia coli K12,.

Authors:  B G Spratt
Journal:  Eur J Biochem       Date:  1977-01

7.  Indirect method for assessing the penetration of beta-lactamase-nonsusceptible penicillins and cephalosporins in Escherichia coli strains.

Authors:  M H Richmond; D C Clark; S Wotton
Journal:  Antimicrob Agents Chemother       Date:  1976-08       Impact factor: 5.191

8.  DNA gyrase: subunit structure and ATPase activity of the purified enzyme.

Authors:  K Mizuuchi; M H O'Dea; M Gellert
Journal:  Proc Natl Acad Sci U S A       Date:  1978-12       Impact factor: 11.205

9.  Nalidixic acid resistance: a second genetic character involved in DNA gyrase activity.

Authors:  M Gellert; K Mizuuchi; M H O'Dea; T Itoh; J I Tomizawa
Journal:  Proc Natl Acad Sci U S A       Date:  1977-11       Impact factor: 11.205

10.  Binding of beta-lactam antibiotics to penicillin-binding proteins of Staphylococcus aureus and Streptococcus faecalis: relation to antibacterial activity.

Authors:  N H Georgopapadakou; F Y Liu
Journal:  Antimicrob Agents Chemother       Date:  1980-11       Impact factor: 5.191

View more
  15 in total

1.  In vitro activity of Ro 23-9424, a dual-action antibacterial agent, against bacterial isolates from cancer patients compared with those of other agents.

Authors:  K V Rolston; H T Nguyen; D H Ho; B LeBlanc; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191

2.  In vitro activity of Ro 23-9424 against clinical isolates of Legionella species.

Authors:  P H Edelstein; M A Edelstein
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

3.  Escherichia coli resistant to cephalosporins and quinolones is still susceptible to the cephalosporin-quinolone ester Ro 23-9424.

Authors:  J Pace; A Bertasso; N H Georgopapadakou
Journal:  Antimicrob Agents Chemother       Date:  1991-05       Impact factor: 5.191

4.  In vitro activity of Ro 24-6392, a novel ester-linked co-drug combining ciprofloxacin and desacetylcefotaxime.

Authors:  R N Jones
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-06       Impact factor: 3.267

5.  In vitro activity of Ro 23-9424, a dual-action cephalosporin, compared with activities of other antibiotics.

Authors:  J W Gu; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1990-02       Impact factor: 5.191

6.  In vitro activities of a dual-action antibacterial agent, Ro 23-9424, and comparative agents.

Authors:  G Beskid; V Fallat; E R Lipschitz; D H McGarry; R Cleeland; K Chan; D D Keith; J Unowsky
Journal:  Antimicrob Agents Chemother       Date:  1989-07       Impact factor: 5.191

7.  Dual-Pharmacophore Pyrithione-Containing Cephalosporins Kill Both Replicating and Nonreplicating Mycobacterium tuberculosis.

Authors:  Landys Lopez Quezada; Kelin Li; Stacey L McDonald; Quyen Nguyen; Andrew J Perkowski; Cameron W Pharr; Ben Gold; Julia Roberts; Kathrine McAulay; Kohta Saito; Selin Somersan Karakaya; Prisca Elis Javidnia; Esther Porras de Francisco; Manuel Marin Amieva; Sara Palomo Dı Az; Alfonso Mendoza Losana; Matthew Zimmerman; Hsin-Pin Ho Liang; Jun Zhang; Veronique Dartois; Stéphanie Sans; Sophie Lagrange; Laurent Goullieux; Christine Roubert; Carl Nathan; Jeffrey Aubé
Journal:  ACS Infect Dis       Date:  2019-06-11       Impact factor: 5.084

Review 8.  Antibiotic Hybrids: the Next Generation of Agents and Adjuvants against Gram-Negative Pathogens?

Authors:  Ronald Domalaon; Temilolu Idowu; George G Zhanel; Frank Schweizer
Journal:  Clin Microbiol Rev       Date:  2018-03-14       Impact factor: 26.132

9.  Low-level resistance to the cephalosporin 3'-quinolone ester Ro 23-9424 in Escherichia coli.

Authors:  J S Chapman; A Bertasso; L M Cummings; N H Georgopapadakou
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

Review 10.  Discovery and development of new antibiotics: the problem of antibiotic resistance.

Authors:  L L Silver; K A Bostian
Journal:  Antimicrob Agents Chemother       Date:  1993-03       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.